CD34-positive pleomorphic uterine sarcoma with NUDT3::RAD51B fusion
- PMID: 40360859
- DOI: 10.1007/s00428-025-04126-1
CD34-positive pleomorphic uterine sarcoma with NUDT3::RAD51B fusion
Abstract
Sarcomas with RAD51B fusions are rare, recently recognized neoplasms that predominantly arise in the uterus. They showed heterogeneous phenotypic features and are typically associated with aggressive biological behaviors. To date, only 14 cases of RAD51B-rearranged sarcomas have been reported in English literature, including 6 perivascular epithelioid cell tumors, 6 leiomyosarcomas, and 2 undifferentiated sarcomas (both uterine in origin). We present an additional case of uterine sarcoma with RAD51B rearrangement. The patient was a 71-year-old woman with a 5.0-cm polypoid mass in the uterine cavity. Histologically, the tumor was composed of spindle to pleomorphic cells arranged in storiform and fascicular patterns within variably myxoid and collagenous stroma. The neoplastic cells had vesicular to hyperchromatic nuclei with occasional multinucleation, with a mitotic rate of 3/10 high-power fields. Notable stromal features included staghorn shaped blood vessels, thick band-like collagen deposition, and prominent chronic inflammatory infiltrates. Immunohistochemically, the tumor cells showed diffuse and strong positivity for CD34, P53, and P16, with focal expression of pan-TRK and smooth muscle actin. Targeted RNA-sequencing revealed NUDT3::RAD51B fusion, which was confirmed by fluorescence in situ hybridization of RAD51B rearrangement. The patient had been free of disease at 22 months' follow-up. This case further illustrates the phenotypic heterogeneity of RAD51B-rearranged sarcomas and expands their clinicopathological and molecular genetic spectrum.
Keywords: NUDT3::RAD51B fusion; CD34; Fluorescence in situ hybridization; Next-generation sequencing; Uterine sarcoma.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics approval: The study was performed in accordance with the Declaration of Helsinki. This study was approved by the Institutional Review Boards Committee from Ningbo Clinical Pathology Diagnosis Center, China. Written informed consent for participation was not required for this study in accordance with the institutional requirements. Competing interests: The authors declare no competing interests.
References
-
- Fadare O (2011) Heterologous and rare homologous sarcomas of the uterine corpus: a clinicopathologic review. Adv Anat Pathol 18:60–74. https://doi.org/10.1097/PAP.0b013e3182026be7 - DOI - PubMed
-
- Croce S, Devouassoux-Shisheboran M et al (2022) Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group. Gynecol Oncol 167:373–389. https://doi.org/10.1016/j.ygyno.2022.07.031 - DOI - PubMed
-
- Bennett JA, Oliva E (2021) Undifferentiated and dedifferentiated neoplasms of the female genital tract. Semin Diagn Pathol 38:137–151. https://doi.org/10.1053/j.semdp.2020.11.002 - DOI - PubMed
-
- Kurihara S, Oda Y, Ohishi Y et al (2008) Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol 32:1228–38. https://doi.org/10.1097/PAS.0b013e31816a3b42 - DOI - PubMed
-
- Croce S, Hostein I, McCluggage WG (2021) E I Hostein WG McCluggage 2021 NTRK and other recently described kinase fusion positive uterine sarcomas: a revi. Genes Chromosomes Cancer 60:147–159. https://doi.org/10.1002/gcc.22910 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
